Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Celgene Corporation : Today's Research Reports on Stocks to Watch: Celgene Corporation and Acceleron Pharma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 02:11pm CEST

NEW YORK, NY / ACCESSWIRE / October 2, 2017 / Celgene and Acceleron both saw their share prices head higher this past Friday after it was learned that Celgene has purchased 750,000 more shares of Acceleron in a public offering. The two companies are partners in a lead program for Luspatercept. Luspatercept is in phase 3 trials for myelodysplastic syndromes and beta-thalassemia, and will remain "our number one priority for the next three years," said Acceleron CEO Habib Dable.

RDI Initiates Coverage on:

Celgene Corporation
https://rdinvesting.com/news/?ticker=CELG

Acceleron Pharma Inc.
https://rdinvesting.com/news/?ticker=XLRN

Celgene Corporation's shares closed up 2.14% this past Friday and came 13 cents shy of hitting their 52-week high. The biopharma company is the largest holder of Acceleron Pharma and is a partner for the company's lead program, Luspatercept, and for sotatercept. It was revealed last week that Celgene purchased 750,000 shares of Acceleron for $28 million. In other news, Celgene and Health2047 have agreed to collaborate to build a data transfer tool for healthcare. Health2047's CEO Dr. Doug GIven said that Celgene is the first of many collaboration partners that will be announced this year. "We are establishing a platform for data transfer with features that are important to Celgene. We have a joint strategy and joint project development teams. We're building apps to address their business needs," he stated.

Access RDI's Celgene Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CELG

Acceleron Pharma Inc.'s shares closed up 4.27% on Friday with about 750,000 shares traded. Celgene made a big purchase in the company. The biotech purchased 750,000 shares of Acceleron in a public offering for $28million. Celgene is still Accerlones largest shareholder and is a partner in a lead program for Luspatercept and Sotatercept. Luspatercept is a potentially first-in-class anemia treatment for MDS and beta-thalassemia that is being developed by Acceleron Pharma in collaboration with Celgene. Sotatercept is also jointly developed with partner Celgene for the treatment of diseases in which anemia is common, but recently the companies changed the amendment of their agreement to give Acceleron the right to develop the drug for pulmonary diseases. CEO Habib Dable recently commented, "Sotatercept will be the lead family in our new pulmonary disease franchise."

Access RDI's Acceleron Pharma Inc. Research Report at:
https://rdinvesting.com/news/?ticker=XLRN

Our Actionable Research on Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
07/12CELGENE : and Acceleron Announce Luspatercept Achieved Primary and Key Secondary..
AQ
07/12CELGENE CORPORATION : - Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Red..
AQ
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11TODAY'S RESEARCH REPORTS ON TRENDING : Galapagos and Celgene
AC
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11ACCELERON PHARMA : Latest luspatercept readout a second win for Acceleron, Celge..
AQ
07/10CELGENE : Health Care Shares Move Higher as Focus Shifts to Earnings -- Health C..
DJ
07/10CELGENE : Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk..
BU
07/10CELGENE : Golumbeski resurfaces, at Grail
AQ
07/09CELGENE CORP /DE/ : Other Events (form 8-K)
AQ
More news
News from SeekingAlpha
03:21aBIOTECH ANALYSIS CENTRAL PHARMA NEWS : Celgene's Protocol Change, Roche's BLA Fo.. 
07/15YOUR DAILY PHARMA SCOOP : Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Pro.. 
07/12Celgene ups dose and enrollment in mid-stage study of bb2121 in multiple myel.. 
07/12Drug prices still marching upward - Bloomberg 
07/11YOUR DAILY PHARMA SCOOP : IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish 
Financials ($)
Sales 2018 14 912 M
EBIT 2018 8 450 M
Net income 2018 4 830 M
Debt 2018 6 033 M
Yield 2018 -
P/E ratio 2018 13,45
P/E ratio 2019 10,63
EV / Sales 2018 4,57x
EV / Sales 2019 3,52x
Capitalization 62 110 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 113 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-17.89%62 110
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193